Items by Blunt, Matthew
|Up a level|
Jump to: Articles
Number of items: 4.
Foster, J.G., Blunt, M.D., Carter, E. and Ward, S.G., 2012. Inhibition of PI3K signaling Spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacological Reviews, 64 (4), pp. 1027-1054.
Blunt, M.D. and Ward, S.G., 2012. Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system:Success, disappointment, and new opportunities. Frontiers in Immunology, 3, 226.
Blunt, M. D. and Ward, S. G., 2012. Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia. Current Opinion in Pharmacology, 12 (4), pp. 444-451.
Harris, S. J., Parry, R. V., Foster, J. G., Blunt, M. D., Wang, A., Marelli-Berg, F., Westwick, J. and Ward, S. G., 2011. Evidence that the lipid phosphatase SHIP-1 regulates T lymphocyte morphology and motility. The Journal of Immunology, 186 (8), pp. 4936-4945.